trending Market Intelligence /marketintelligence/en/news-insights/trending/GSaku9yjpV6M8RXjNb9mAA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Aeterna Zentaris hires advisers to evaluate options for drug Macrilien

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Aeterna Zentaris hires advisers to evaluate options for drug Macrilien

Aeterna Zentaris Inc.'s strategic review committee engaged a consulting firm and a financial adviser to help evaluate options to maximize shareholder value.

The company said the firms were hired in part to validate the commercial potential of Macrilien, its orphan drug for adult growth hormone deficiency. Options that may be considered include entering into partnerships or building an internal sales force, raising capital including through an investment from a strategic partner, or selling some or all of the company and its assets.

Newly appointed CEO Michael Ward has taken steps to reduce overhead in the coming months, including reducing or eliminating expenses associated with the company's discontinued Zoptrex product.

The company added that there is no assurance that evaluation of strategic alternatives will result in a transaction.